ASH 2018 | MRD highlights in myeloma from ASH 2018
Ola Landgren
Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, NY, gives his insight into the measurable residual disease (MRD) data from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Related videos
2:43 Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn
2:43 Pivotal STORM study: selinexor for penta-refractory multiple myeloma
Joshua Richter
2:43 Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter
2:43 Multiple myeloma musings: highlights from 2018 data
Joshua Richter
2:43 An exciting era for CAR T-cell therapy
Mohamad Mohty
